{"disease":{"id":"severe-myoclonic-epilepsy-in-infancy","name":"Severe myoclonic epilepsy in infancy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cannabidiol","indication_name":"Severe myoclonic epilepsy in infancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epidiolex","generic_name":"CANNABIDIOL","company_name":"Jazz Pharms Res","drug_phase":"marketed","molecular_target":"Caspase-1","drug_class":"","quality_score":69,"revenue":"800","mechanism":"Epidiolex works by inhibiting the activity of caspase-1, a protein involved in the inflammatory response and neuronal excitability."},{"drug_id":"epidiolex","indication_name":"Severe myoclonic epilepsy in infancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epidiolex","company_name":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","drug_phase":"marketed","molecular_target":"N-arachidonyl glycine receptor, Cannabinoid receptor 2, Caspase-1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}